Altimmune (NASDAQ:ALT) Posts Quarterly Earnings Results

Altimmune (NASDAQ:ALT - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.36) by $0.02, Zacks reports. Altimmune had a negative return on equity of 44.77% and a negative net margin of 20,780.75%. The business had revenue of $0.01 million during the quarter. During the same quarter in the previous year, the company earned ($0.40) EPS.

Altimmune Stock Down 6.5 %

NASDAQ ALT traded down $0.50 during trading hours on Friday, hitting $7.22. 3,042,224 shares of the company were exchanged, compared to its average volume of 5,087,175. The stock has a market cap of $511.86 million, a PE ratio of -4.38 and a beta of 0.22. The stock has a 50-day moving average price of $8.69 and a 200 day moving average price of $7.80. Altimmune has a 52 week low of $2.09 and a 52 week high of $14.84.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Guggenheim lowered shares of Altimmune from a "buy" rating to a "neutral" rating in a report on Monday, April 29th. The Goldman Sachs Group started coverage on shares of Altimmune in a report on Wednesday, January 24th. They set a "neutral" rating and a $13.00 price objective for the company. JMP Securities cut their price objective on Altimmune from $25.00 to $24.00 and set a "market outperform" rating for the company in a research report on Friday. B. Riley restated a "buy" rating and set a $20.00 price target on shares of Altimmune in a report on Thursday, March 28th. Finally, HC Wainwright decreased their price objective on Altimmune from $15.00 to $12.00 and set a "buy" rating on the stock in a report on Monday, April 1st. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $17.25.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.